Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestin controversy may encourage challenges of other source botanicals -- AHPA.

This article was originally published in The Tan Sheet

Executive Summary

CHOLESTIN CONTROVERSY MAY ENCOURAGE CHALLENGES OF OTHER BOTANICALS containing small amounts of old or new drug ingredients, the American Herbal Products Association suggests in Jan. 30 comments to FDA. "AHPA is concerned that the present controversy could create incentives for those who develop new drugs from botanicals to attack the regulatory status of the source botanical once the pharmaceutical grade new drug has been approved," the association states. FDA has suggested to marketer Pharmanex that Cholestin's lovastatin content renders the product an unapproved new drug.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel